AAV production service: titre, purity and empty capsids

Specifying the preparation

1. Serotype and the packaging limit. Serotype determines tropism and is chosen from the target tissue and route. The packaging capacity is a hard limit on the genome, and a construct over it produces truncated genomes rather than a warning, so confirm the total size including the inverted terminal repeats and regulatory elements early.
2. Titre is method dependent. Genome-containing particles measured by amplification, total capsids measured immunologically and infectious units measured in cells are three different numbers. Ask which method is used, on which standard, and prefer providers who report more than one so the preparation can be understood.
3. Empty and full capsid ratio. Empty capsids carry no genome, contribute to the immune load and dilute the effective dose. The full to empty ratio should be measured and reported per lot, and a preparation with a poor ratio needs a higher total dose to achieve the same delivery.
4. Purification route. Density gradient separation enriches full capsids and is slower; chromatography scales better and varies in how well it separates empties. Ask which route is used and what ratio it achieves, since this is the largest quality difference between providers.
5. Residuals and endotoxin. Residual host cell protein and DNA, residual plasmid and helper sequences, and endotoxin should all have stated limits and lot results, particularly for in vivo work where they drive the response as much as the vector does.

Custom AAV production: research grade against material for regulated use

Research grade preparations are made without a quality system and cannot be used to support a regulated application later. If a programme may move that way, ask now what would change and at what cost, because the process, the documentation and the testing all differ.

Plasmid quality feeds directly into vector quality, so where the programme is heading toward regulated use the plasmids need attention at the same time as the vector.

AAV testing: what an AAV service delivers

Verify titre in your own hands where you can, and always test a small aliquot for function before committing an experiment or an animal cohort. Provider titres are measured by the provider's method against the provider's standard.

Keep a retained aliquot of every lot. A change in results between lots cannot be investigated without one, and vector lots vary more than most reagents.

Titre from AAV services is a method, not a number

A genome-containing particle count, a total capsid count and an infectious unit count are three different measurements of the same preparation and they differ by orders of magnitude. A titre quoted without its method cannot be compared with another, and dosing on the wrong one is the commonest reason an in vivo experiment is uninterpretable.

State the method, the assay's reference material and its precision. Between laboratories, the same preparation measured by the same nominal method can differ severalfold, which is why a reference standard is used for anything where the dose has to be reproducible.

AAV empty capsids, AAV aggregation and what the dose really contains

Preparations contain capsids with no genome as well as full ones, and the ratio varies with the process. Empty capsids contribute to the antigen load without contributing expression, so the ratio matters for both potency and immunogenicity and is a specification rather than a curiosity.

Aggregation raises the apparent particle count, reduces infectivity and causes loss on filters, and it is driven by concentration, buffer and freeze-thaw. Both are measured during characterisation, and a vendor who will not report either is reporting less than the preparation's quality.

Counting infectious particles

A plaque count measures particles that destroy cells in a monolayer, which suits lytic viruses and not vectors that do not kill. An endpoint dilution assay measures the dilution at which half the cultures show an effect and works where plaques do not form. A neutralisation assay measures serum's ability to block infection rather than the virus itself.

Each is a bioassay with a wide confidence interval, so replicates and a reference preparation matter more than the decimal places. Where a release specification depends on one, its qualification is part of the method rather than an afterthought.

Replication competence as a release test

A vector preparation has to be shown free of replication-competent particles, which is a sensitive assay run over several passages in permissive cells. It is required for clinical material and it is slow, which is why it appears late in a programme and surprises people.

Ask a supplier what limit their assay reaches and over how many passages, and whether the assay has been qualified for your construct. The answer decides both the timeline and the cost of a batch release.

aav empty full measurement and why the ratio matters

The aav empty full ratio reports how many capsids carry a genome, and it matters because empty capsids add antigen load without dose, so a titre alone can hide a poor preparation. It is measured by analytical ultracentrifugation, by charge detection mass spectrometry or by the ratio of genome to capsid titres, and the method belongs beside the number.

Common questions

Why does the empty capsid ratio matter?

Empty capsids carry no genome, so they dilute the effective dose and add to the immune load without delivering anything. The full to empty ratio should be measured and reported for every lot.

Which titre method should I ask for?

Ask which is used, because genome-containing particles, total capsids and infectious units are three different numbers. Providers reporting more than one give you a preparation you can actually understand.

What limits construct size in AAV packaging services?

The packaging capacity of the capsid, counting the whole genome including the inverted terminal repeats and regulatory elements. Exceeding it produces truncated genomes rather than an error, so confirm the total early.

Can research grade AAV support a regulated application later?

No. Material for regulated use needs a different process, documentation and testing package, and it cannot be applied retrospectively. Ask what would change before the programme commits.

Why do two titres for the same preparation differ so much?

Because they measure different things: genome-containing particles, total capsids and infectious units differ by orders of magnitude. A titre without its method is not comparable, and dosing on the wrong one makes an in vivo result uninterpretable.

Does the empty to full ratio matter?

Yes, for potency and for antigen load: empty capsids contribute immunogenicity without expression. It is a specification, and so is aggregation, which raises apparent particle count and lowers infectivity.

Browse by service class

• Compare Gene synthesis on advertised prices